Tuesday, November 6, 2012
The FDA's Office of Prescription Drug Promotion, Division of Professional Drug Promotion issued a letter to ONY Inc., of Amherst, N.Y., stating that materials on its website are false or misleading because they present unsubstantiated superiority claims for Infasurf, omit important risk information and make unsubstantiated claims for the product.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.